Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...

Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...

Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited earnings conference call. My name is Alex, I'll be ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Call Transcript November 6, 2024 Teva Pharmaceutical ...

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), boosting ...

Teva Pharmaceutical (TEVA) stock gains in premarket after the company posted better than expected Q3 2024 financials and ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...